Actigraphy Improvement With Voxelotor (ActIVe) Study

PHASE4CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

December 21, 2020

Primary Completion Date

September 8, 2022

Study Completion Date

September 13, 2022

Conditions
Sickle Cell DiseaseSickle Cell Anemia
Interventions
DRUG

Voxelotor

500 mg Tablet, Oral, With or Without Food

Trial Locations (10)

10029

Icahn School of Medicine at Mount Sinai, New York

10476

The Children's Hospital at Montefiore, The Bronx

15213

University of Pittsburgh Medical Center, Pittsburgh

23298

VCU Health, Richmond

27710

Duke Department of Pediatrics, Durham

30342

Children's Healthcare of Atlanta, Atlanta

43210

The Ohio State University Wexner Medical Center, Columbus

48201

Children's Hospital of Michigan, Detroit

77030

The University of Texas Health Science Center at Houston, Houston

06030

UConn Health, Farmington

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT04400487 - Actigraphy Improvement With Voxelotor (ActIVe) Study | Biotech Hunter | Biotech Hunter